Revenue (Tables)

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Product

Revenue by product for the periods indicated were as follows:

	Twelve Months Ended December 31,
(In thousands)	2025		2024
CHEMOSAT	$	6,396	$	4,902
HEPZATO KIT	78,835		32,303
Total revenue	$	85,231	$	37,205

The following table shows the disaggregated revenue by geographic location for the twelve months ended December 31, 2025 and 2024. No individual foreign country is material to the consolidated results.

	Twelve Months Ended December 31,
	2025		2024
Foreign	$	6,396	$	4,902
United States	78,835		32,303
Total revenue	$	85,231	$	37,205

Schedule of Revenue and Accounts Receivable Concentrations

The Company’s total percentage of revenue and accounts receivable balances were comprised of the following concentrations from its largest customers, based on whose revenue or accounts receivable concentration is greater than 10% of total revenue or total accounts receivable in the periods disclosed below.

For the twelve months ended and as of December 31, 2025	% of Revenue		% of Accounts Receivable
Customer 1	15.2	%	24.0	%

For the twelve months ended and as of December 31, 2024	% of Revenue		% of Accounts Receivable
Customer 1	20.1	%	10.1	%
Customer 2	17.7	%	30.2	%
Customer 3	13.2	%	3.4	%
Customer 4	11.3	%	16.8	%